Based on our results, RCE as a PD-1/PD-L1 blockade and Oxa combination therapy could be a driving force for preclinical research studies in patients with CRC, supporting the efficacy of cancer immunotherapies. This evidence concerns the gene PDCD1 and colorectal carcinoma.